Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sonos (NASDAQ: SONO ) stock is on the rise Monday after the speaker company got a favorable ruling from a judge in a patent battle with Alphabet’s (NASDAQ: GOOGL , GOOG ) Google. Source: ClassyPic...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Travere Therapeutics (NASDAQ: TVTX ) stock is on the rise Monda and it’s all thanks to positive interim results from one of its Phase 3 clinical trials. Source: Shutterstock This study sees Travere Ther...
Gainers: NanoVibronix NAOV +44%, Nymox Pharmaceutical (NASDAQ:NYMX) +21%, Travere Therapeutics TVTX +20%, Enlivex Therapeutics ENLV +15%, Collegium Pharmaceutical COLL +11%. Losers: Sesen Bio SESN -35%, ESSA Pharma EPIX -32...
While Wall Street largely focused on macro issues in Monday's pre-market period, including the ongoing headlines out of Afghanistan, some individual stocks moved on company-specific news. Tesla (NASDAQ:TSLA) was the highest-profile of these, losing ground as its autopilot feature has received...
Sparsentan treatment group experienced 49.8 percent mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator; interim primary efficacy endpoint achieved, p<0.0001 To date in the study, sparsentan has been generally well-...
Travere Therapeutics, Inc. (TVTX) Q2 2021 Results Conference Call July 29, 2021 04:30 PM ET Company Participants Chris Cline - SVP, IR & Corporate Communications Dr. Eric Dube - CEO Dr. Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - CFO Dr. B...
Travere Therapeutics (NASDAQ:TVTX): Q2 Non-GAAP EPS of -$0.39 beats by $0.11; GAAP EPS of -$0.64 beats by $0.04. Revenue of $54.62M (+12.8% Y/Y) beats by $4.29M. As of June 30, 2021, the Company had cash, cash equivalents and marketable securities of $522.8 million. Press Release For furthe...
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track to report topline data from interim 36-week proteinuria endpoint in August 2021 ...
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discus...
Shares of Travere Therapeutics Inc. (NASDAQ:TVTX) traded at a new 52-week low today of $13.10. So far today approximately 130,000 shares have been exchanged, as compared to an average 30-day volume of 898,000 shares. Travere Therapeutics Inc is a biopharmaceutical company. The company is...
News, Short Squeeze, Breakout and More Instantly...
Travere Therapeutics Inc Com Company Name:
TVTX Stock Symbol:
NASDAQ Market:
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...
2024-04-15 06:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...